发明授权
US08822647B2 Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
有权
使用嵌合抗原受体的增强T细胞抗肿瘤效应子功能的方法和组合物
- 专利标题: Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
- 专利标题(中): 使用嵌合抗原受体的增强T细胞抗肿瘤效应子功能的方法和组合物
-
申请号: US13060908申请日: 2009-08-26
-
公开(公告)号: US08822647B2公开(公告)日: 2014-09-02
- 发明人: Michael Jensen
- 申请人: Michael Jensen
- 申请人地址: US CA Duarte
- 专利权人: City of Hope
- 当前专利权人: City of Hope
- 当前专利权人地址: US CA Duarte
- 代理机构: Rothwell, Figg, Ernst & Manbeck P.C.
- 国际申请: PCT/US2009/055029 WO 20090826
- 国际公布: WO2010/025177 WO 20100304
- 主分类号: C07K16/46
- IPC分类号: C07K16/46 ; C07K19/00 ; C12N5/0783 ; C12N5/22 ; C12N15/63 ; A61P35/00
摘要:
Integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor (CAR), such as the IL13Rα2 specific IL13-zetakine (IL13ζ), enhances T cell-mediated responses against tumors even in the absence of expressed ligands for costimulatory receptors.